Jaguar Health (NASDAQ: JAGX) CFO discloses RSU and option equity grants

Q: What insider equity awards were reported for Jaguar Health (JAGX) CFO?

Jaguar Health’s Chief Financial Officer, Carol R. Lizak , reported receiving 11,740 restricted stock units and stock options for 11,740 shares of common stock on December 11, 2025 .

Q: How many restricted stock units did the Jaguar Health (JAGX) CFO receive and when do they vest?

The CFO received 11,740 restricted stock units . Each unit represents a contingent right to receive one share of voting common stock, and the units vest on December 11, 2026 .

Q: What are the key terms of the stock options granted to the Jaguar Health (JAGX) CFO?

The stock options cover 11,740 shares of common stock at an exercise price of $1.44 per share. They expire on December 11, 2035 and vest ratably on a monthly basis over 12 months from the grant date, conditioned on continued employment.

Q: How many Jaguar Health (JAGX) common shares were reported as beneficially owned after the transaction?

Following the reported transaction, the filing shows 11,911 shares of common stock as beneficially owned by the reporting person.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Jaguar Health, Inc. reported that its Chief Financial Officer, Carol R. Lizak, received new equity awards on December 11, 2025.

The awards include 11,740 restricted stock units, each representing a contingent right to receive one share of voting common stock for $0 consideration, with beneficial ownership of common stock reported as 11,911 shares after the transaction. She also received stock options to purchase 11,740 shares of common stock at an exercise price of $1.44 per share, expiring on December 11, 2035.

The grants were made under the company’s 2014 Stock Incentive Plan. The restricted stock units vest on December 11, 2026, and vested shares will be delivered on that vesting date, while the options vest in equal monthly installments over 12 months from the grant date, subject to continued employment.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Lizak Carol R.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	11,740	$0.00	--
Grant/Award	Common Stock	11,740	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 11,740 shares (Direct); Common Stock — 11,911 shares (Direct)

Footnotes (1)

Granted pursuant to the issuer's 2014 Stock Incentive Plan. The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025. Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice. On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split"). Upon effectiveness of the Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock. The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer.

Form 4 Insider Transactions: What Each Field Means →

12/15/2025 - 05:46 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lizak Carol R.

(Last)

(First)

(Middle)

C/O JAGUAR HEALTH, INC.

200 PINE ST., STE 400

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Jaguar Health, Inc. [ JAGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock⁽¹⁾	12/11/2025⁽²⁾⁽³⁾		A		11,740	A	$0	11,911⁽⁴⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)⁽¹⁾	$1.44	12/11/2025⁽²⁾		A		11,740		⁽⁵⁾	12/11/2035	Common Stock	11,740	$0	11,740	D

Explanation of Responses:

1. Granted pursuant to the issuer's 2014 Stock Incentive Plan.

2. The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.

3. Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice.

4. On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split"). Upon effectiveness of the Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock.

5. The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer.

	/s/ Carol R. Lizak	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider equity awards were reported for Jaguar Health (JAGX) CFO?

Jaguar Health’s Chief Financial Officer, Carol R. Lizak, reported receiving 11,740 restricted stock units and stock options for 11,740 shares of common stock on December 11, 2025.

How many restricted stock units did the Jaguar Health (JAGX) CFO receive and when do they vest?

The CFO received 11,740 restricted stock units. Each unit represents a contingent right to receive one share of voting common stock, and the units vest on December 11, 2026.

What are the key terms of the stock options granted to the Jaguar Health (JAGX) CFO?

The stock options cover 11,740 shares of common stock at an exercise price of $1.44 per share. They expire on December 11, 2035 and vest ratably on a monthly basis over 12 months from the grant date, conditioned on continued employment.

Under which plan were the Jaguar Health (JAGX) CFO’s equity awards granted?

The restricted stock units and stock options granted to the CFO were issued under Jaguar Health’s 2014 Stock Incentive Plan.

How many Jaguar Health (JAGX) common shares were reported as beneficially owned after the transaction?

Following the reported transaction, the filing shows 11,911 shares of common stock as beneficially owned by the reporting person.

What reverse stock split did Jaguar Health (JAGX) disclose in relation to its common stock?

Jaguar Health disclosed that on March 24, 2025, it effected a 25-for-1 reverse stock split, in which every 25 shares of voting common stock were automatically converted into one share.